Related Experiment Video
Updated: Oct 4, 2025
07:05
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
8.4K
A Broad m6A Modification Landscape in Inflammatory Bowel Disease.
Kai Nie1,2, Jun Yi3, Yuanyuan Yang1,2
1Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, China.
Frontiers in Cell and Developmental Biology
|February 7, 2022
Summary
N6-Methyladenosine (m6A) regulation is implicated in inflammatory bowel disease (IBD) development. This study reveals m6A modifications in IBD risk genes and immune cytokines, influencing disease phenotypes.
Area of Science:
- Epigenetics and Molecular Biology
- Gastroenterology and Immunology
Background:
- N6-Methyladenosine (m6A) is the most prevalent mRNA modification, impacting gene expression.
- The specific role of m6A regulation in the pathogenesis of inflammatory bowel diseases (IBD) remains largely uncharacterized.
Purpose of the Study:
- To investigate the m6A RNA methylation landscape in inflammatory bowel diseases.
- To explore the association between m6A regulators, IBD risk genes, and immune responses.
Main Methods:
- Analysis of multiple human IBD microarray and RNA-seq datasets.
- Measurement of m6A regulators in colonic tissue samples.
- Application of consensus clustering and immune scoring to characterize m6A regulation in IBD.
Main Results:
- m6A regulators showed differential expression in IBD cohorts, with common genes identified (IGF2BP2, HNRNPA2B1, ZCCHC4, EIF3I).
- m6A modifications were found in IBD risk loci and core immune cytokines.
- Distinct immune phenotypes and clinical differences were associated with m6A regulation patterns in IBD patients.
Conclusions:
- m6A methylation regulation plays a significant role in the occurrence and development of IBD.
- m6A modifications in genetic risk factors, immune mediators, and proteins likely influence IBD pathophysiology and clinical presentation.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
01:30Inflammatory Bowel Disease II: Crohn's Disease
435
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
435
01:29Inflammatory Bowel Disease IV: Pharmacological Management
221
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
221
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
392
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
392
01:29Drugs for Treatment of Ulcerative Colitis in IBD
256
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
256
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
443
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
443